Patents by Inventor ELI LILLY AND COMPANY

ELI LILLY AND COMPANY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130217762
    Abstract: The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof.
    Type: Application
    Filed: October 5, 2012
    Publication date: August 22, 2013
    Applicant: ELI LILLY AND COMPANY
    Inventor: Eli Lilly and Company
  • Publication number: 20130197039
    Abstract: The present invention provides compounds of Formula below: and analogues thereof where the various substituent groups, R1, R2, R3, R4, R5 A, and X are described herein; or a pharmaceutical salt thereof; a method of treating a condition such as hypertriglyceridemia and a process for preparing the compounds.
    Type: Application
    Filed: January 24, 2013
    Publication date: August 1, 2013
    Applicant: Eli Lilly and Company
    Inventor: Eli Lilly and Company
  • Publication number: 20130164304
    Abstract: Monoclonal antibodies are provided that selectively bind human hepcidin-25 and are characterized as having high affinity for human hepcidin-25 and strong human mature hepcidin neutralizing properties. The antibodies of the invention are useful therapeutically for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment and diagnosis of mature hepcidin-promoted disorders such as anemia, in a human subject.
    Type: Application
    Filed: December 7, 2012
    Publication date: June 27, 2013
    Applicant: ELI LILLY AND COMPANY
    Inventor: Eli Lilly and Company
  • Publication number: 20130131017
    Abstract: This invention provides novel compounds, methods of using the compounds, and pharmaceutical compositions containing the compounds.
    Type: Application
    Filed: November 16, 2012
    Publication date: May 23, 2013
    Applicants: Anacor Pharmaceuticals, Inc., Eli Lilly and Company
    Inventors: Eli Lilly and Company, Anacor Pharmaceuticals, Inc.
  • Publication number: 20130131016
    Abstract: This invention provides novel compounds, methods of using the compounds, and pharmaceutical formulations comprising the compounds.
    Type: Application
    Filed: November 16, 2012
    Publication date: May 23, 2013
    Applicants: Anacor Pharmaceuticals, Inc., Eli Lilly and Company
    Inventors: Eli Lilly and Company, Anacor Pharmaceuticals, Inc.
  • Publication number: 20130085098
    Abstract: This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.
    Type: Application
    Filed: September 25, 2012
    Publication date: April 4, 2013
    Applicant: ELI LILLY AND COMPANY
    Inventor: ELI LILLY AND COMPANY
  • Publication number: 20130039996
    Abstract: An improved method for treating gastric cancer, ovarian cancer, non-small cell lung cancer, or colorectal cancer in a patient is described, as well as pharmaceutical compositions useful for the method and a process for preparing said compositions.
    Type: Application
    Filed: October 18, 2012
    Publication date: February 14, 2013
    Applicant: ELI LILLY AND COMPANY
    Inventor: ELI LILLY AND COMPANY